Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 507-513

  Puig, Noemi ^a   Wang, Lisa ^a   Seshadri, Tara ^a   Al Farsi, Khalil ^a   Keating, Armand ^a   Crump, Michael ^a   Kuruvilla, John ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

ASCT; PTCL; Refractory; Relapsed; Salvage

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ELECTROCORTICOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; STEM CELL MOBILIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL, PERIPHERAL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873330937     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.719615     Document Type: Article

References (37)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classifcation Project. Blood 1997;89: 3909-3918.
2. Harris NL, Jafe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84: 1361-1392.
3. Melnyk A, Rodríguez A, Pugh WC, et al. Evaluation of the revised European-American lymphoma classification conf rms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997;89: 4514-4520.
4. López-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol 1998;9: 849-855.
5. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic signif cance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'études des lymphomas de l'adulte (GELA). Blood 1998: 92: 76-82.
6. Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project. Ann Oncol 2002;13: 140-149.
7. Armitage JO, Vose JM, Linder J, et al. Clinical signif cance of immunophenotype in dif use aggressive non-Hodgkin's lymphoma. J Clin Oncol 1989;7: 1783-1790.
8. Coifer B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etudes des Lymphomes Aggressives). Ann Oncol 1990: 1: 45-50.
9. Rodríguez J, Munsell M, Yazji S, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001;19: 3766-3770.
10. Kewalramani T, Nimer S, Zelenetz A, et al. Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and dif use large B-cell lymphoma (DLBCL) treated with autologous transplantation (ASCT). Blood 2002;100: 646a.
11. Caballero MD, Pérez-Simon JA, Iriondo A, et al. High-dose therapy in dif use large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003;14: 140-151.
12. Blystad AK, Enblad G, Kvaloy S, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T-cell lymphomas. Bone Marrow Transplant 2001: 27: 711-716.
13. Angelopoulou MK, Nademanee A, Davis A, et al. Comparison of outcome of high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) in peripheral T cell lymphoma (PTCL) vs. DLBCL (B-DLCL). Blood 2003;102: 247a.
14. Song KW, Mollee P, Keating A, et al. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003;120: 978-985.
15. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapsed or chemotherapy-sensitive non-Hodgkin lymphoma. N Engl JMed 1995;333: 1540-1545.
16. Jafe ES, Harris NL, Stein H, et al. World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press: 2001.
17. Gascoyne RD, Aoun P, Wu D, et al. Prognostic signif cance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93: 3913-3921.
18. Falini B, Pileri S, Zinzani PL, et al. ALK+lymphoma: clinico-pathological findings and outcome. Blood 1999: 93: 2697-2706.
19. Rodríguez J, Cabanillas F, McLaughlin P, et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the "tumor score ". Ann Oncol 1992;3: 711-717.
20. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103: 2474-2479.
21. Lister TA, Crowther D, Sutclife SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswoldsmeeting. J Clin Oncol 1989;7: 1630-1636.
22. Cheson BD, Horning SJ, Coifer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17: 1244.
23. Jostig A, Ruefer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96: 1280-1286.
24. Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993;11: 704-711.
25. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998;16: 3264-3269.
26. Jantunen E, Wiklund T, Juvonen E, et al. Autologous stem cell transplantation in adults patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004;33: 405-410.
27. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006: 134: 202-207.
28. Smith SD, Bolwell BJ, Rybicki LA, et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 2007;40: 239-243.
29. Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007;40: 443-450.
30. Rodríguez J, Conde E, GutiérrezA, et al. The adjusted International Prognostic Index and ß-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007: 92: 1067-1074.
31. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007: 25: 2764-2769.
32. O'Connor OA, Hamlin PA, Portlock C, et al. Pralatrexate, a novel class of antifol with high af nity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007;139: 425-428.
33. Cheson BD. Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. Curr Opin Hematol 2009: 16: 299-305.
34. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results ofaphase II study. JClin Oncol 2012;30: 2190-2196.
35. Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma Effect for aggressive T-cell lymphomas in adults: a study by the Soci ét éFrancaise de Gref e de Mo ëlle et de Térapie Cellulaire. J Clin Oncol 2008;26: 2264-2271.
36. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma Effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation ofhematopoietic cells. J Clin Oncol 2004;22: 2172-2176.
37. Kyriakou C, Canals C, Finke J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27: 3951-3958.